Characteristics of HIV type 1 (HIV-1) glycoprotein 120 env sequences in mother-infant pairs infected with HIV-1 subtype CRF01_AE

Journal of Infectious Diseases

Volumn 198, Issue 6, 2008, Pages 868-876

  Samleerat, Tanawan ^a,i   Braibant, Martine ⁱ   Jourdain, Gonzague ^b,c   Moreau, Alain ⁱ   Ngo Giang Huong, Nicole ^b,c   Leechanachai, Pranee ^a   Hemvuttiphan, Jittapol ^d   Hinjiranandana, Temsiri ^e   Changchit, Tikamporn ^f   Warachit, Boonyarat ^g   Suraseranivong, Veera ^h   Lallemant, Marc ^b,c   Barin, Francis ^i,j  

^a CHIANG MAI UNIVERSITY   (Thailand)

^b Institute of research for development Thailand   (Thailand)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d Phayao Hospital   (Thailand)

^e Somdej Pranangchao Sirikit Hospital   (Thailand)

^f Phan Hospital   (Thailand)

^g Hat Yai Hospital   (Thailand)

^h BHUMIBOL ADULYADEJ HOSPITAL   (Thailand)

ⁱ UNIVERSITÉ DE TOURS   (France)

^j CHU BRETONNEAU   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 120;

ADULT; ARTICLE; CLINICAL ARTICLE; ENVELOPE GENE; FEMALE; GENE CLUSTER; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC VARIABILITY; GLYCOSYLATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFANT; MOTHER FETUS RELATIONSHIP; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; UNINDEXED SEQUENCE; VIRUS TRANSMISSION;

DISEASE TRANSMISSION, VERTICAL; FEMALE; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; INFANT, NEWBORN; POLYMERASE CHAIN REACTION; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; VARIATION (GENETICS);

EID: 51749087085     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/591251     Document Type: Article

References (48)

1. John GC, Kreiss J. Mother-to-child transmission of human immunodeficiency virus type 1. Epidemiol Rev 1996; 18:149-57.
2. Kourtis AP, Lee FK, Abrams EJ, Jameson DJ, Bulterys M. Mother-to-child transmission of HIV-1: timing and implications for prevention. Lancet Infect Dis 2006; 6:726-32.
3. Thorne C, Newell ML. Mother-to-child transmission of HIV infection and its prevention. Curr HIV Res 2003; 1:447-62.
4. Lallemant M, Jourdain G, LeCoeur S, et al. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med 2004; 351:217-28.
5. McIntyre J. Strategies to prevent mother-to-child transmission of HIV. Curr Opin Infect Dis 2006; 19:33-8.
6. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373:123-6.
7. Preston BD, Dougherty JP. Mechanisms of retroviral mutation. Trends Microbiol 1996; 4:16-21.
8. Rambaud A, Posada D, Crandall KA, Holmes EC. The causes and consequences of HIV evolution. Nat Rev Genet 2004; 5:52-61.
9. Frost SDW, Wrin T, Smith DM, et al. Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc Natl Acad Sci USA 2005; 102:18514-9.
10. Shankarappa R, Margolick JB, Gange SJ, et al. Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol 1999; 73:10489-502.
11. Burton DR, Stanfield RL, Wilson IA. Antibody vs. HIV in a clash of evolutionary titans. Proc Natl Acad Sci USA 2005; 102:14943-8.
12. Wolinsky SM, Wike CM, Korber BT, et al. Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants. Science 1992; 255:1134-7.
13. Scarlatti GT, Leitner E, Halapi J, et al. Comparison of variable region 3 sequences of human immunodeficiency virus type 1 from infected children with the RNA and DNA sequences of the virus populations of their mothers. Proc Natl Acad Sci USA 1993; 90:1721-5.
14. Ahmad N, Baroudy BM, Baker RC, Chappey C. Genetic analysis of human immunodeficiency virus type 1 envelope V3 region isolates from mothers and infants after perinatal transmission. J Virol 1995; 69:1001-12.
15. Pasquier C, Cayrou C, Blancher A, et al. Molecular evidence for mother-to-child transmission of multiple variants by analysis of RNA and DNA sequences of human immunodeficiency virus type 1. J Virol 1998; 72:8493-501.
16. Verhofstede C, Demecheleer E, De Cabooter N, et al. Diversity of the human immunodeficiency virus type 1 (HIV-1) env sequence after vertical transmission in mother-child pairs infected with HIV-1 subtype A. J Virol 2003; 77:3050-7.
17. Scarlatti G, Albert J, Rossi P, et al. Mother-to-child transmission of human immunodeficiency virus type 1: correlation with neutralizing antibodies against primary isolates. J Infect Dis 1993; 168:207-10.
18. Lathey JL, Tsou J, Brinker K, Hsia K, Meyer WA III, Spector SA. Lack of autologous neutralizing antibody to human immunodeficiency virus type 1 (HIV-1) and macrophage tropism are associated with mother-to-infant transmission. J Infect Dis 1999; 180:344-50.
19. Bongertz V, Costa CI, Veloso VG, et al. Neutralization titres and vertical HIV-1 transmission. Scand J Immunol 2002; 56:642-4.
20. Guevara H, Casseb J, Zijenah LS, et al. Maternal HIV-1 antibody and vertical transmission in subtype C virus infection. J Acquir Immune Defic Syndr 2002; 29:435-40.
21. Barin F, Jourdain G, Brunet S, et al. Revisiting the role of neutralizing antibodies in mother-to-child transmission of the HIV-1. J infect Dis 2006; 193:1504-11.
22. Dickover R, Garratty E, Yusim K, Miller C, Korber B, Bryson Y. Role of maternal autologous neutralizing antibody in selective perinatal transmission of human immunodeficiency virus type 1 escape variants. J Virol 2006; 80:6525-33.
23. Wu X, Parast AB, Richardson BA, et al. Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant. J Virol 2006; 80:835-44.
24. Dickover RE, Garratty EM, Plaeger S, Bryson YJ. Perinatal transmission of major, minor, and multiple maternal human immunodeficiency virus type 1 variants in utero and intrapartum. J Virol 2001; 75:2194-203.
25. Lamers SL, Sleasman JW, She JX, et al. Persistence of multiple maternal genotypes of human immunodeficiency virus type I in infants infected by vertical transmission. J Clin Invest 1994; 93:380-90.
26. Renjifo B, Chung M, Gilbert P, et al. In-utero transmission of quasispecies among human immunodeficiency virus type 1 genotypes. Virology 2003; 307:278-82.
27. Derdeyn CA, Decker JM, Bibollet-Ruche F, et al. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 2004; 303:2019-22.
28. Chohan B, Lang D, Sagar M, et al. Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels. J Virol 2005; 79:6528-31.
29. Frost SDW, Liu Y, Pond SL, et al. Characterization of human immunodeficiency virus type 1 (HIV-1) envelope variation and neutralizing antibody responses during transmission of HIV-1 subtype B. J Virol 2005; 79:6523-7.
30. Li B, Decker JM, Johnson RW, et al. Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1. J Virol 2006; 80:5211-8.
31. Lallemant M, Jourdain G, Le Coeur S, et al. A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. Perinatal HIV Prevention Trial (Thailand) Investigators. N Engl J Med 2000; 343:982-91.
32. Bryson YJK, Luzuriaga JL, Sullivan JL, Wara DW. Proposed definitions for in utero versus intrapartum transmission of HIV-1. N Engl J Med 1992; 327:1246-7.
33. Hall TA. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucl Acids Symp Ser 1999; 41:95-8.
34. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position specific gap penalties and weight matrix choice. Nucleic Acids Res 1994; 22:4673-80.
35. Los Alamos National Laboratory. HIV databases. Available at: http://www.hiv.lanl.gov/content/index. Accessed 13 July 2008.
36. Kumar S, Tamura K, Nei M. MEGA3: integrated software for Molecular Evolutionary Genetics Analysis and sequence alignment. Brief Bioinform 2004; 5:150-63.
37. Los Alamos National Laboratory. N-GlycoSite. Available at: http://www.hiv.lanl.gov/content/sequence/GLYCOSITE/glycosite.html. Accessed 13 July 2008.
38. Kimura M. A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences. J Mol Evol 1980; 16:111-20.
39. Tovanabutra S, de Souza M, Sittisombut N, et al. HIV-1 genetic diversity and compartmentalization in mother/infant pairs infected with CRF01_AE. AIDS 2007; 21:1050-3.
40. Blish CA, Nedellec R, Mandaliya K, Mosier DE, Overbaugh J. HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry. AIDS 2007; 21:693-702.
41. Dacheux L, Moreau A, Ataman-Onal Y, Biron F, Verrier B, Barin F. Evolutionary dynamics of the glycan shield of the human immunodeficiency virus envelope during natural infection and implication for exposure of the 2G12 epitope. J Virol 2004; 78:12625-37.
42. Scanlan CN, Offer J, Zitzmann N, Dwek RA. Exploiting the defensive sugars of HIV-1 for drug and vaccine design. Nature 2007; 446:1038-45.
43. Wei X, Decker JM, Wang S, et al. Antibody neutralization and escape by HIV-1. Nature 2003; 422:307-12.
44. Sutthent R, Foongladda S, Chearskul S, et al. V3 sequence diversity of HIV-1 subtype E in infected mothers and their infants. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18:323-31.
45. Kiszka I, Kmieciak D, Gzyl J, et al. Effect of the V3 loop deletion of envelope glycoprotein on cellular responses and protection against challenge with recombinant vaccinia virus expressing gp160 of primary human immunodeficiency virus type 1 isolates. J Virol 2002; 76:4222-32.
46. Koch M, Pancera M, Kwong PD, et al. Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition. Virology 2003; 313:387-400.
47. Malenbaum SE, Yang D, Cavacini L, Posner M, Robinson J, Cheng-Mayer C. The N-terminal V3 loop glycan modulates the interaction of clade A and B human immunodeficiency virus type 1 envelopes with CD4 and chemokine receptors. J Virol 2000; 74:11008-16.
48. Van Kooyk Y, Engering A, Lekkerkerker AM, Ludwig IS, Geijtenbeek TBH. Pathogens use carbohydrates to escape immunity induced by dendritic cells. Curr Opin Immunol 2004; 16:488-93.